Patient info Open main menu

Meropenem Qilu 500 mg powder for solution for injection/infusion – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
500 mg
Contains active substance:
ATC code:
Similar medicines:

Patient leaflet - Meropenem Qilu 500 mg powder for solution for injection/infusion

1. What Meropenem Qilu is and what it is used for

Meropenem Qilu contains the active substance meropenem and belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria, which can cause serious infections.

Meropenem Qilu is used to treat the following infections in adults and children aged 3 months and older:

  • Infection affecting the lungs (pneumonia)
  • Lung and bronchial infections in patients suffering from cystic

    fibrosis (inherited condition in which the lungs and digestive system can become clogged with thick, sticky mucus) • Complicated urinary tract infections

  • Complicated infections in the abdomen (stomach) • Infections that you can catch during or after the delivery • Complicated skin and soft tissues infections • Serious bacterial infection of the brain (meningitis)

This medicine may be used in the management of neutropenic patients (with weakened immune system) with fever that is suspected to be due to a bacterial infection.

Package leaflet: Information for the user

Meropenem Qilu 500 mg powder for solution for injection / infusion

meropenem

The following information is intended for medical or healthcare professionals only:

Instructions for giving Meropenem Qilu to yourself or someone else at home

Some patients, parents and carers are trained to give Meropenem Qilu at home.

Warning – You should only give this medicine to yourself or someone else at home after a doctor or nurse has trained you.

How to prepare this medicine

  • The medicine must be mixed with another liquid (the

    diluent). Your doctor will tell you how much of the diluent to use.

  • Use the medicine straight after preparing it. Do not freeze it.
  • Wash your hands and dry them very well. Prepare a clean

    working area.

  • Remove the Meropenem Qilu vial from the packaging.

    Check the vial and the expiry date. Check that the vial is intact and has not been damaged.

  • Remove the cap and clean the rubber stopper with an

    alcohol wipe. Allow the rubber stopper to dry.

  • Connect a new sterile needle to a new sterile syringe,

    without touching the ends.

  • Draw up the recommended amount of sterile ‘Water for

    Injections’ into the syringe. The amount of liquid that you need is shown in the table below:

Dose of

Meropenem Qilu

Amount of ‘Water for Injections’ needed for dilution

500 mg 10 ml

1 g 20 ml

1.5 g 30 ml

2 g 40 ml

Please note: If your prescribed dose of Meropenem Qilu is more than 1 g, you will need to use more than 1 vial of Meropenem Qilu. You can then draw the liquid in the vials into the one syringe.

  1. 6.

    Put the needle of the syringe through the centre of the

    rubber stopper and inject the recommended amount of ‘Water for Injections’ into the vial or vials of Meropenem Qilu.

  2. 7.

    Remove the needle from the vial and shake the vial well

    for about 5 seconds, or until all the powder has dissolved. Clean the rubber stopper once more with a new alcohol wipe and allow the rubber stopper to dry.

  3. 8.

    With the plunger of the syringe pushed fully into the

    syringe, put the needle back through the rubber stopper. You must then hold both the syringe and the vial and turn the vial upside down.

  4. 9.

    Keeping the end of the needle in the liquid, pull back the

    plunger and draw all the liquid in the vial into the syringe.

  5. 10.

    Remove the needle and syringe from the vial and throw the

    empty vial away in a safe place.

  6. 11.

    Hold the syringe upright, with the needle pointing upwards.

    Tap the syringe so that any bubbles in the liquid rise to the top of the syringe.

  7. 12.

    Remove any air in the syringe by gently pushing the

    plunger until all the air has gone.

  8. 13.

    If you are using Meropenem Qilu at home, dispose of

    any needles and infusion lines that you have used in an appropriate way. If your doctor decides to stop your treatment, dispose of any unused Meropenem Qilu in an appropriate way.

Giving the injection

You can either give this medicine through a short cannula, or intravenous catheter, or through a port or central line.

Giving Meropenem Qilu through a short cannula or intravenous catheter

  1. 1.

    Remove the needle from the syringe and throw the needle

    away carefully in your sharps bin.

  2. 2.

    Wipe the end of the short cannula or intravenous catheter

    with an alcohol wipe and allow it to dry. Open the cap on your cannula and connect the syringe.

  3. 3.

    Slowly push the plunger of the syringe to give the antibiotic

    steadily over about 5 minutes.

  4. 4.

    Once you have finished giving the antibiotic and the

    syringe is empty, remove the syringe and use a flush as recommended by your doctor or nurse.

  5. 5.

    Close the cap of your cannula and carefully throw the

    syringe away in your sharps bin.

Giving Meropenem Qilu through a port or central line

  1. 1.

    Remove the cap on the port or line, clean the end of the

    line with an alcohol wipe and allow it to dry.

  2. 2.

    Connect the syringe and slowly push the plunger on the

    syringe to give the antibiotic steadily over about 5 minutes.

  3. 3.

    Once you have finished giving the antibiotic, remove the

    syringe and use a flush as recommended by your doctor or nurse.

  4. 4.

    Place a new clean cap on your central line and carefully

    throw the syringe away in your sharps bin.

Posology and method of administration

Posology

The tables below provide general recommendations for dosing.

The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.

A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. Enterobacterales, Pseudomonas aeruginosa, Acinetobacter spp.), or very severe infections.

Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).

Adults and adolescents

Infection Dose to be administered every 8 hours

Severe pneumonia including hospital-

acquired and ventilator-associated

pneumonia.

500 mg or 1 g

Broncho-pulmonary infections in cystic

fibrosis

2 g

Complicated urinary tract infections 500 mg or 1 g

Complicated intra-abdominal infections 500 mg or 1 g

Intra- and post-partum infections 500 mg or 1 g

Complicated skin and soft tissue infections 500 mg or 1 g

Acute bacterial meningitis 2 g

Management of febrile neutropenic patients 1 g

Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes.

Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2000 mg dose in adults as an intravenous bolus injection. Meropenem Qilu may be used to treat bacterial infection of the blood which might be associated with a type of infection mentioned above.

2. What you need to know before you use Meropenem Qilu

Do not use Meropenem Qilu

  • if you are allergic to meropenem or any of the other

    ingredients of this medicine (listed in section 6). • if you are allergic to other antibiotics such as penicillins,

    cephalosporins, or carbapenems as you may also be allergic to meropenem.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using Meropenem Qilu

  • if you have health problems, such as liver or kidney

    problems.

  • if you have had severe diarrhoea after taking other antibiotics.

Blood tests

You may develop a positive blood test (Coombs test) which indicates the presence of antibodies that may destroy red blood cells.

Your doctor will discuss this with you.

Skin reactions

You may develop signs and symptoms of severe skin reactions (see section 4). If this happens talk to your doctor or nurse immediately so that they can treat the symptoms.

Serious muscle problems

If you notice unexplained muscle pain, tenderness or weakness and/or dark coloured urine tell your doctor immediately. This may be a sign of muscle breakdown (called rhabdomyolysis) which may lead to kidney problems.

Liver problems

If you notice yellowing of the skin and eyes, itchy skin, dark-coloured urine or light-coloured stool tell your doctor. This may be a sign of liver problems which your doctor needs to check.

If you are not sure if any of the above applies to you, talk to your doctor or nurse before using this medicine.

Other medicines and Meropenem Qilu

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is because Meropenem Qilu can affect the way some medicines work and some medicines can have an effect on Meropenem Qilu.

In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines:

  • Probenecid (used to treat gout).
  • Valproic acid/sodium valproate/valpromide (used to treat

    epilepsy). Meropenem Qilu should not be used because it may decrease the effect of sodium valproate. • Oral anti-coagulant medicine(used to treat or prevent blood

    clots).

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. It is preferable to avoid the use of meropenem during pregnancy. Your doctor will decide whether you should use Meropenem Qilu.

It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving Meropenem Qilu. Small amounts of this medicine may pass into the breast milk. Therefore, your doctor will decide whether you should use Meropenem Qilu while breast-feeding.

Driving and using machines

No studies on the effect on the ability to drive and use machines have been performed.

Meropenem has been associated with headache and tingling or pricking skin (paraesthesia). Any of these side effects could affect your ability to drive or operate machines.

This medicine may cause involuntary muscle movements which may cause the person’s body to shake rapidly and uncontrollably (fits). This is usually accompanied with a loss of consciousness. Do not drive or use machines if you experience this side effect.

Meropenem Qilu contains sodium

This medicine contains 45 mg sodium (main component of cooking/table salt) in each 500 mg dose. This is equivalent to 2.25 % of the recommended maximum daily dietary intake of sodium for an adult.

If you have a condition which requires you to monitor your sodium intake please inform your doctor, pharmacist or nurse.

3. How to use Meropenem Qilu

Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.

Use in adults

  • The dose depends on the type of infection that you have, where the infection is in the body and how serious the infection is. Your doctor will decide on the dose that you need.
  • The dose for adults is usually between 500 mg and 2 g. You will usually receive a dose every 8 hours. However, you may receive a dose less often if your kidneys do not work very well.

Use in children and adolescents

The dose for children over 3 months old and up to 12 years of age is decided using the age and weight of the child. The usual dose is between 10 mg and 40 mg of meropenem for each kilogram (kg) that the child weighs. A dose is usually given every 8 hours. Children who weigh over 50 kg will be given an adult dose.

How to use Meropenem Qilu

  • Meropenem Qilu will be given to you as an injection or infusion into a large vein.
  • Your doctor or nurse will normally give Meropenem Qilu to you.
  • However, some patients, parents and carers are trained to give Meropenem Qilu at home. Instructions for doing this are provided in this leaflet (in the section called ‘Instructions for giving Meropenem Qilu to yourself or someone else at home’). Always use Meropenem Qilu exactly as your doctor has told you. You should check with your doctor if you are not sure.
  • Your injection should not be mixed with or added to solutions that contain other medicines.
  • The injection may take about 5 minutes or between 15 and

    30 minutes. Your doctor will tell you how to give Meropenem Qilu.

  • You should normally have your injections at the same times each day.

If you use more Meropenem Qilu than you should

If you accidentally use more than your prescribed dose, contact your doctor or nearest hospital straight away.

If you forget to use Meropenem Qilu

If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection. Do not have a double dose (two injections at the same time) to make up for a forgotten dose.

If you stop using Meropenem Qilu

Do not stop using Meropenem Qilu until your doctor tells you to.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

D

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Severe allergic reactions

If you have any of these signs and symptoms, tell your doctor or nurse straight away. You may need urgent medical treatment. The signs and symptoms may include a sudden onset of: • Severe rash, itching or hives on the skin.

  • Swelling of the face, lips, tongue or other parts of the body. • Shortness of breath, wheezing or trouble breathing. • Serious skin reactions which include

    • Serious allergicreactions involving fever, skin rash, and

      changes in the blood tests that check how the liver is working (increased levels of liver enzymes) and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes. These may be signs of a multi-organ sensitivity disorder known as DRESS syndrome. - Severe red scaly rash, skin bumps that contain pus,

      blisters or peeling of skin, which may be associated with a high fever and joint pains.

    • Severe skin rashes that can appear as reddish circular

      patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome) or a more severe form (toxic epidermal necrolysis).

Damage to red blood cells

The signs include:

  • Being breathless when you do not expect it • Red or brown urine

If you notice any of the above, see a doctor straight away.

Muscle breakdown

  • Unexplained muscle pain, tenderness or weakness, and/or

    dark coloured urine.

If you notice these signs or symptoms, see a doctor straight away.

Other possible side effects:

Common (may affect up to 1 in 10 people)

  • Abdominal (stomach) pain
  • Feeling sick (nausea)
  • Being sick (vomiting)
  • Diarrhoea
  • Headache
  • Skin rash, itchy skin
  • Pain and inflammation (swelling at the injection site) • Increased numbers of platelets in your blood (shown in a

    blood test).

  • Changes in blood tests, including tests that show how well

    your liver is working.

Renal impairment

The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the administration of these dose adjustments for a unit dose of 2 g.

Creatinine clearance

(ml/min)

Dose

(based on “unit” dose

range of 500 mg or

1 g or 2 g, see table above)

Frequency

26-50 one unit dose every 12 hours

10-25 half of one unit dose every 12 hours

<10 half of one unit dose every 24 hours

Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.

There are no established dose recommendations for patients receiving peritoneal dialysis.

Hepatic impairment

No dose adjustment is necessary in patients with hepatic impairment.

Dose in elderly patients

No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.

Paediatric population

Children under 3 months of age

The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen.

PN-06507 / Meropenem UK_500mg_PIL_390x380mm_9pt_Rev.12_28.05.26 SET B Children from 3 months to 11 years of age and up to 50 kg body weight

The recommended dose regimens are shown in the table below:

Infection Dose to be

administered every 8 hours

Severe pneumonia including hospital-

acquired and ventilator-associated

pneumonia

10 or 20 mg/kg

Broncho-pulmonary infections in cystic

fibrosis

40 mg/kg

Complicated urinary tract infections 10 or 20 mg/kg

Complicated intra-abdominal infections 10 or 20 mg/kg

Complicated skin and soft tissue infections 10 or 20 mg/kg

Acute bacterial meningitis 40 mg/kg

Management of febrile neutropenic patients 20 mg/kg

Children over 50 kg body weight

The adult dose should be administered.

There is no experience in children with renal impairment.

Method of administration

For intravenous use.

After reconstitution/dilution Meropenem Qilu is usually given by intravenous infusion over approximately 15 to 30 minutes. Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.

Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section “Special precautions for disposal and other handling”.

After reconstitution/dilution:

Intravenous bolus injection administration

Reconstituted solution of the medicinal product in water for injection should be used immediately.

Intravenous infusion administration

Chemical and physical in-use stability of the medicinal product in sodium chloride 9 mg/ml (0.9 %) solution for infusion has been demonstrated for 1 hour at 25oC and 5 hours at 2 to 8oC.

From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. The time interval between the beginning of reconstitution and the end of intravenous infusion should not exceed one hour.

Reconstituted solution of the medicinal product in glucose 50 mg/ml (5 %) solution should be used immediately.

Do not freeze the reconstituted solution.

Special precautions for disposal and other handling

Injection

Meropenem to be used for bolus intravenous injection should be reconstituted with sterile water for injection.

Infusion

For intravenous infusion meropenem vials may be directly reconstituted with sodium chloride 9 mg/ml (0.9 %) or glucose 50 mg/ml (5 %) solution for infusion.

Each vial is for single use only.

Standard aseptic techniques should be used for solution preparation and administration.

The solution should be shaken before use.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Uncommon (may affect up to 1 in 100 people)

  • Changes in your blood. These include reduced numbers of

    platelets (which may make you bruise more easily), an increased numbers of some white blood cells, decreased numbers of other white cells and increased amounts of a substance called ‘bilirubin’. Your doctor may do blood tests from time to time. • Changes in blood tests, including tests that show how well

    your kidney is working

  • A tingling feeling (pins and needles)
  • Infections of the mouth or the vagina that are caused by a

    fungus (thrush)

  • Inflammation of the bowel with diarrhoea
  • Sore veins where Meropenem Qilu is injected • Other changes in your blood. The symptoms include

    frequent infections, high temperature and sore throat. Your doctor may do blood tests from time to time. • Reduced levels of potassium in your blood (which can

    cause weakness, muscle cramps, tingling and heart rhythm disturbances).

  • Liver problems. Yellowing of the skin and eyes, itchy skin,

    dark-coloured urine or light-coloured stool. If you notice these signs or symptoms, see a doctor straight away.

Sudden chest pain, which may be a sign of a potentially serious allergic reaction called Kounis syndrome has been noted with other medicines of the same type. If this happens talk to a doctor or nurse immediately.

Rare (may affect up to 1 in 1,000 people)

  • Fits (convulsions)
  • Acute disorientation and confusion (delirium)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website:www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Meropenem Qilu

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

After reconstitution/dilution:

Intravenous bolus injection administration

Reconstituted solution of the medicinal product in water for injection should be used immediately.

Intravenous infusion administration

Chemical and physical in-use stability of the medicinal product in sodium chloride 9 mg/ml (0.9%) solution for infusion has been demonstrated for 1 hour at 25oC and 5 hours at 2 to 8oC.

From a microbiological point of view, unless the method of opening/ reconstitution/dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. The time interval between the beginning of reconstitution and the end of intravenous infusion should not exceed one hour.

Reconstituted solution of the medicinal product in glucose 50 mg/ml (5 %) solution should be used immediately.

Do not freeze the reconstituted solution.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What Meropenem Qilu contains

  • The active substance is meropenem.

    Each vial contains meropenem trihydrate equivalent to 500 mg anhydrous meropenem.

  • The other ingredient is sodium carbonate.

What Meropenem Qilu looks like and contents of the pack

Meropenem Qilu is a white to light yellow crystalline powder for solution for injection/infusion in a vial. Pack sizes of 1 or 10 vials. Not all pack sizes may be marketed.

Marketing Authorisation Holder

QILU PHARMA SPAIN S.L.

Paseo de la Castellana 40, planta 8,

28046 Madrid,

Spain

Manufacturer

KYMOS, S.L.

Ronda de Can Fatjó,

7B (Parque Tecnológico del Vallès),

Cerdanyola del Vallès, 08290, Barcelona,

Spain

Distributed by

Sun Pharma UK Limited

6-9 The Square

Stockley Park

Uxbridge

UB11 1FW

This leaflet was last revised in 05/2026

Advice/medical education

Antibiotics are used to treat infections caused by bacteria. They have no effect against infections caused by viruses. Sometimes an infection caused by bacteria does not respond to a course of an antibiotic. One of the commonest reasons for this to occur is because the bacteria causing the infection are resistant to the antibiotic that is being taken. This means that they can survive and even multiply despite the antibiotic.

Bacteria can become resistant to antibiotics for many reasons. Using antibiotics carefully can help to reduce the chance of bacteria becoming resistant to them.

When your doctor prescribes a course of an antibiotic it is intended to treat only your current illness. Paying attention to the following advice will help prevent the emergence of resistant bacteria that could stop the antibiotic working.

  1. 1. It is very important that you take the antibiotic at the right dose, at the right times and for the right number of days. Read the instructions on the label and if you do not understand anything ask your doctor or pharmacist to explain.
  2. 2. You should not take an antibiotic unless it has been prescribed specifically for you and you should use it only to treat the infection for which it was prescribed.
  3. 3. You should not take antibiotics that have been prescribed for other people even if they had an infection that was similar to yours.
  4. 4. You should not give antibiotics that were prescribed for you to other people.
  5. 5. If you have any antibiotic left over when you have taken the course as directed by your doctor you should take the remainder to a pharmacy for appropriate disposal.

Code-Nr.: 34160034911D

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 44570/0028

Last revision stated in the text: May 2026 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Meropenem Qilu 500 mg powder for solution for injection/infusion

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Meropenem
Strength 500 mg
Pharmaceutical form Powder for solution for injection
White to light yellow crystalline powder.
How is it taken Intravenous
Excipients Sodium carbonate
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
After reconstitution/dilution:
Intravenous bolus injection administration
Reconstituted solution of the medicinal product in water for injection should be used immediately.
Intravenous infusion administration
Chemical and physical in-use stability of the medicinal product in sodium chloride 9 mg/ml (0.9%) solution for infusion has been demonstrated for 1 hour at 25°C and 5 hours at 2 to 8°C.
From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. The time interval between the beginning of reconstitution and the end of intravenous infusion should not exceed one hour.
Reconstituted solution of the medicinal product in glucose 50 mg/ml (5%) solution should be used immediately.
Do not freeze the reconstituted solution.
Storage This medicinal product does not require any special storage conditions.
For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.
Drug group (ATC) Antibacterials for systemic use, carbapenems
  1. J Antiinfectives for systemic use
    1. J01 Antibacterials for systemic use
      1. J01D Other beta-lactam antibacterials
        1. J01DH Carbapenems
          1. J01DH02 meropenem
Marketing authorisation PL 44570/0028 (first authorised 8 September 2023)
Marketing authorisation holder QILU PHARMA SPAIN S.L.
Codes BNF 05010202

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.